MISSISSAUGA, Ontario--(BUSINESS WIRE)--Jun 26, 2023--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it is participating in the 2023 APIC Annual Conference and Exposition in Orlando, Florida from June 26 to 28, 2023. Healthcare providers looking to strengthen their infection prevention toolkit with patient-centered medical technology should visit Covalon at booth 612 to learn more about Covalon’s unique compassionate care solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230626454700/en/
IV Clear® dressing applied to an IV insertion site, and VALGuard® applied to a line connection. Contamination of IV setups is a common source of catheter-related bloodstream infections and require special handling procedures and protection to minimize health risks to patients. (Photo: Business Wire)
APIC, the Association for Professionals in Infection Control and Epidemiology, is the leading professional association for infection preventionists (IPs), with more than 15,000 members. The conference brings together more than 3,000 nurses, physicians, public health professionals, academia, epidemiologists, microbiologists, medical technologists, and industry to advance knowledge sharing, collaboration, and scientific innovation in the area of infection prevention and control.
“Providing patients thorough protection against infections should not come at the compromise of providing gentle, compassionate care,” said Ron Hebert, Senior Vice President, Marketing, Covalon. “Healing shouldn’t hurt, which is why at Covalon we are laser focused on developing medical technology that gives patients their best defense against infection, without causing unnecessary pain, trauma, or tears.”
Covalon representatives will be available to meet with participants on site. To make an appointment, please contact Ron Hebert, SVP Marketing, at rhebert@covalon.com.
Covalon’s suite of infection prevention solutions include:
- VALGuard® - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
- IV Clear® - the world’s only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
Conference details
Dates: Monday, June 26 to Wednesday, June 28, 2023
Venue: Orange County Convention Center (9800 International Drive, Orlando, FL 32819)
Registration: https://www.mcisemi.com/apic2023
For healthcare providers who are not able to attend the conference but are interested in learning more about Covalon’s solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2022, which is available on the Company’s profile atwww.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230626454700/en/
CONTACT: Brian Pedlar, CEO, Covalon Technologies Ltd.
bpedlar@covalon.com
905.568.8400 x 233
Toll-Free: 1.877.711.6055
https://covalon.com/
Twitter:@covalon
KEYWORD: UNITED STATES NORTH AMERICA CANADA FLORIDA
INDUSTRY KEYWORD: NURSING MANAGED CARE MEDICAL SUPPLIES SURGERY HEALTH MEDICAL DEVICES INFECTIOUS DISEASES HOSPITALS
SOURCE: Covalon Technologies Ltd.
Copyright Business Wire 2023.
PUB: 06/26/2023 07:30 AM/DISC: 06/26/2023 07:31 AM
http://www.businesswire.com/news/home/20230626454700/en
